Status:
COMPLETED
Development and Validation of a Simulator-based Test in Transurethral Resection of Bladder Tumors
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Copenhagen Academy for Medical Education and Simulation
Conditions:
Validity-evidence for a Simulator-based Test
Virtual Simulation
Eligibility:
All Genders
Brief Summary
Bladder cancer (BC) is the seventh most common cancer in men worldwide and fourth most common cancer among Danish men. BC is estimated to be the most cost expensive cancer pr. patient life. BC is diag...
Detailed Description
The incidence of bladder tumors is increasing and is more than 2,000 in Denmark. The bladder tumor is initially treated by transurethral resection (TURB) classifying the tumor by debt of invasion. The...
Eligibility Criteria
Inclusion
- Novice: Residents with no individual experience in TUR-B defined as no prior hands-on surgical experience in TURB.
- Intermediates: Residents who have performed 10 to 30 TURBs.
- Experienced: Consultants with experience in the procedure defined as more than 100 TURBs.
- All participants: Reasonable Danish skills and must give informed written consent to participate.
Exclusion
- Exclusion criteria for all participants: Prior systematic experience on the Simbionix/VirtaMed UroSimTM simulator.
Key Trial Info
Start Date :
March 15 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 21 2018
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT03863028
Start Date
March 15 2018
End Date
September 21 2018
Last Update
March 5 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Copenhagen Academy for Medical Education and Simulation
Copenhagen, Danmark, Denmark, 2100
2
Urology Department, Zealand University Hospital
Roskilde, Denmark, DK-4000